ADVERTISEMENT
Market Intelligence
While Roche admits that an acceleration of biosimilar competition to its blockbuster IL-6 inhibitor Actemra/RoActemra is anticipated in the final three months of the year, the Swiss originator has been surprised by the lack of challenge to its franchise so far.
During Q3, biopharmas brought in an aggregate $17bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.1m.
Roche’s 2022-launched Vabysmo took no time at all to reach the coveted $1bn in sales, and the originator is continuing to feel optimistic about the newer-generation VEGF brand’s prospects, even as Amgen readies the launch of the first US biosimilar to Eylea.
Keytruda and Ozempic held their positions as the number one and two best-selling drugs in the world in the second quarter, while Eli Lilly’s Mounjaro shot to sixth place.
An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
September saw the extreme price rises of the last few months subside in the UK, albeit still seeing a handful of treble-digit percentage average increases for products like telmisartan.
Italian personal care and beauty manufacturer Sodalis Group will acquire Alberto V05, Zest soap, Sure deodorants and other personal care brands in a transaction with current owner Tengram Capital Partners expected to close by the end of October. Recent years have seen high private equity activity in cosmetics and personal care.
In the latest episode of the In Vivo podcast, Russ Lebovitz, the co-founder and scientist behind San Diego's Amprion Diagnostics, discusses the role alpha-synuclein misfolding plays in neurodegenerative diseases and how early alpha-synuclein testing could mitigate the impacts of conditions ranging from Parkinson's disease to Lewy body dementia.
Exosome-based treatments hold promise, but their reality has not yet materialized in the form of compelling clinical data. Belgian biotech Exo Biologics’ CEO Hugues Wallemacq believes his company can help move the field forward, both through its own clinical programs and by offering high-quality exosomes to others in the field.